Abstract Details

Title Balloon Expandable Stents Versus Self-expanding Stents for Treatment of Intracranial Arterial Stenosis: A Systematic Review and Meta-analysis

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P1 - Poster Session 1 (8:00 AM-9:00 AM)

Poster/Presentation
Number 5-022

Objective Our study aimed to determine a more precise treatment effect of balloon-expanding stents (BES) compared with self-expanding stents (SES) than be derived from considering each study with a small sample size individually.

Background There is limited data regarding the comparison of balloon-expanding stents (BES) and self-expanding stents (SES) for the treatment of intracranial arterial stenosis.

Design/Methods We conducted a systematic review to identify studies that compared SES and BES in patients with symptomatic intracranial arterial stenosis. Data were extracted from relevant studies found through a search of PubMed, Scopus, and Web of Science until May 2023. Statistical pooling with random-effects meta-analysis was undertaken to compare the rates/severity of post-procedure stenosis, technical success, stroke and/or mortality, long-term events, and restenosis rates between BES and SES.

Results A total of 20 studies were included. The standardized mean difference (SMD) for post-procedure stenosis (%) was significantly lower (SMD: -0.52, 95% confidence interval [CI]: -0.79 to -0.24, p < 0.001, 10 studies involving 1515 patients) with BES. The odds for technical success were non-significantly lower (odds ratio [OR]: 0.99, 95% CI 0.43-2.26, p = 0.983, 9 studies involving 1001 patients) with BES. The odds for post-procedure 30-day stroke and/or death were significantly lower (OR 0.68, 95% CI: 0.50-0.94, p = 0.019, 15 studies involving 2431 patients), and stroke and/or death beyond 30 days were non-significantly lower (OR 0.64, 95% CI: 0.30-1.37, p = 0.250, 10 studies involving 947 patients) with BES. The odds for restenosis rate were significantly lower (OR 0.50, 95% CI: 0.31-0.80, p = 0.004, 13 studies involving 1115 patients) with BES.

Conclusions Compared with SES, BES were associated with lower rates of post-procedure 30-day stroke and/or death presumably due to less severe post procedure stenosis in treatment of symptomatic intracranial arterial stenosis.

Authors/Disclosures
Abdullah Lodhi PRESENTER	No disclosure on file
Xiaoyu Ma	No disclosure on file
Rehan Ahmed	No disclosure on file
Jahanzeb Liaqat (Pakistan Military)	No disclosure on file
Hamza Maqsood, MBBS (University of Missouri)	Mr. Maqsood has nothing to disclose.
Chun Kwok	No disclosure on file
Ameer Hassan, DO (Valley Baptist Medical Center)	Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medtronic. Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Stryker. Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Penumbra. Dr. Hassan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Cerenovus. Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Viz.ai. Dr. Hassan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Hassan has received research support from GE Healthcare.
Farhan Siddiq, MD	Dr. Siddiq has nothing to disclose.
Camilo R. Gomez, MD, FAAN (University of Missouri)	Dr. Gomez has nothing to disclose.
Muhammad F. Suri, MD (St Cloud Hospital)	Dr. Suri has nothing to disclose.
Hamza I. Maqsood, MD (Dept of Neurology)	Dr. Qureshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca.

��ɫ��

��ɫ��